Financial Performance - Total revenue for the year ended December 31, 2024, was RMB 325.359 million, an increase from RMB 246.29 million in 2023, representing a growth of approximately 32%[5] - Gross profit for the same period was RMB 17.072 million, compared to RMB 16.093 million in 2023, indicating a gross margin improvement[5] - The net loss attributable to owners of the company for the year was RMB 4.158 million, reduced from a loss of RMB 5.782 million in the previous year, showing a decrease in loss of approximately 28%[5] - The company’s basic and diluted loss per share improved to RMB 0.86 from RMB 1.39 in the previous year, indicating better performance on a per-share basis[5] - The company reported a loss before tax of RMB 4,158,000 for the year ended December 31, 2024, compared to a loss of RMB 5,782,000 for the year ended December 31, 2023, indicating a reduction in losses[26] - The group reported a loss attributable to owners of approximately RMB 4.2 million for the fiscal year ending December 31, 2024, a decrease of approximately RMB 1.6 million or about 28.1% from the previous year[61] Revenue Breakdown - Revenue from male infertility in vitro diagnostic reagents was RMB 19,365,000, up from RMB 19,033,000 in the previous year, indicating a growth of about 1.75%[16] - Revenue from the parasite series testing reagents increased to RMB 3,761,000 from RMB 3,059,000, reflecting a significant growth of approximately 22.93%[16] - The revenue from the bioreagents and assisted reproductive products segment reached RMB 25.4 million, a growth of 4.3% compared to 2023, with core product sales increasing by 1.7% to RMB 19.4 million[47] - The sales of male infertility in vitro diagnostic reagents accounted for approximately 76.4% of the total revenue in the biopharmaceuticals and assisted reproductive products and equipment segment, with revenue of approximately RMB 25.4 million, up about RMB 1.0 million or approximately 4.3% from the previous year[52] Research and Development - Research and development expenses increased to RMB 2.825 million from RMB 2.553 million, reflecting a focus on innovation and product development[5] - Research and development expenses for the year ended December 31, 2024, were RMB 2,825,000, reflecting the company's commitment to innovation[19] - Research and development expenses increased by approximately RMB 272,000 or about 10.7% to approximately RMB 2.8 million, mainly due to costs associated with improving existing products and developing a sperm morphology analysis testing kit[59] Assets and Liabilities - Total assets as of December 31, 2024, were RMB 54.723 million, slightly up from RMB 53.436 million in 2023[6] - The total equity of the company increased to RMB 54.048 million from RMB 51.019 million, reflecting a stronger financial position[7] - The total assets as of December 31, 2024, amounted to RMB 65,222,000, while total liabilities were RMB 11,174,000, resulting in a net asset position[19] - The company’s total liabilities increased from RMB 14,296,000 in 2023 to RMB 11,174,000 in 2024, indicating a decrease in financial leverage[21] Cash Flow and Liquidity - Cash and cash equivalents at year-end were RMB 31.495 million, down from RMB 32.935 million in the previous year[6] - As of December 31, 2024, the group had cash and bank balances totaling approximately RMB 36.5 million, an increase from approximately RMB 32.9 million the previous year, primarily due to collections from receivables[62] - The company has adopted a prudent treasury policy to manage its cash balance and maintain healthy liquidity for future growth opportunities[68] Share Capital and Equity - The weighted average number of ordinary shares increased to 482,436,384 in 2024 from 415,962,411 in 2023, an increase of approximately 16%[34] - The total issued share capital as of December 31, 2024, is projected to be RMB 4,432,000[43] - As of December 31, 2024, the total issued shares of the company are 500,472,000[88] Corporate Governance - The company has established an audit committee consisting of three independent non-executive directors[87] - The audit committee has reviewed the audited consolidated financial statements and confirmed compliance with applicable accounting standards[87] - The company has confirmed compliance with the GEM listing rules regarding the minimum public float of 25% since its listing date[79] Future Plans and Strategy - The company plans to continue focusing on market expansion and new product development to drive future growth[4] - The company plans to acquire Hunan Keyue Biotechnology Co., which has rich R&D experience and product lines in the domestic women's health market, to diversify its business[49] - The company aims to integrate its international resources with local capabilities through the acquisition of Keyue Biotechnology, targeting the growing demand in the women's health market[51] - The company will deepen technology development and explore emerging markets such as Southeast Asia to drive growth and create sustainable value for shareholders[51] Compliance and Legal Matters - The company has not engaged in any purchases, sales, or redemptions of its listed securities as of December 31, 2024[77] - There are no significant legal proceedings or arbitrations involving the company as of December 31, 2024[80]
华康生物医学(08622) - 2024 - 年度业绩